Stuart Dorman
About Stuart Dorman
Stuart C. Dorman, 47, is Chief Commercial Officer of IDEAYA Biosciences, serving since December 2024. He previously led U.S. oncology commercial operations at Gilead and held global oncology commercialization leadership at Bristol Myers Squibb; he holds an MBA from Stanford GSB and an AB in Economics from Harvard University . In 2024, IDEAYA’s pay-versus-performance disclosure shows strong shareholder returns (company TSR value of a fixed $100 investment rose to 183.57 vs. peer TSR 93.49) alongside a net loss of $274.5M and year-end liquidity of ~$1.08B, contextualizing performance-linked pay outcomes that included Dorman’s prorated bonus .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Gilead Sciences | Vice President, US Oncology Business Unit Head | Oct 2020–Nov 2024 | Led U.S. oncology commercial unit at a leading biopharma |
| Bristol Myers Squibb | Various commercial roles incl. VP, Oncology Worldwide Commercialization | Jul 2006–Oct 2020 | Senior commercialization leadership in global oncology |
| Trinity Partners LLC | Senior Consultant and Manager | 1999–2004 | Life sciences strategy consulting |
External Roles
No public company directorships or external board roles were disclosed for Mr. Dorman in the proxy biography .
Fixed Compensation
| Year | Base Salary (Annualized) | Salary Paid (FY 2024) | Target Bonus % | Target Bonus ($) | Actual Bonus Paid ($) | Sign-on Bonus ($) | All Other Compensation ($) |
|---|---|---|---|---|---|---|---|
| 2024 | $500,000 | $41,667 (Dec 2–31, 2024) | 40% | $200,000 | $20,000 | $100,000 | $150 (cell phone allowance) |
Performance Compensation
Annual Cash Bonus Structure (FY 2024)
| Metric Category | Weighting | Target ($) | Actual Achievement (%) | Payout ($) | Notes |
|---|---|---|---|---|---|
| Clinical & Preclinical objectives (IDE397, IDE161, Pol Theta, Werner Helicase, early discovery) | 70% | $200,000 | Not disclosed | $20,000 | Specific goals not disclosed to avoid competitive harm; intended to be difficult |
| Corporate development (US launch readiness for darovasertib, balance sheet enhancement, IR/infra) | 30% | $200,000 | Not disclosed | Included in above $20,000 | Committee retains discretion on achievement |
Equity Awards (FY 2024)
| Award Type | Grant Date | Shares/Options | Exercise Price | Grant-Date Fair Value | Vesting | Expiration |
|---|---|---|---|---|---|---|
| Stock Options (2019 Plan) | 12/2/2024 | 170,000 | $27.45 | $3,258,441 | 25% after first anniversary of vesting commencement date; remaining 75% in equal monthly installments over next 36 months (1/48th per month), subject to continued service | Not disclosed |
Equity program emphasizes long-term alignment; exercise price set at grant-date closing price; peer group and internal equity considered; annual grants typically use Jan 1 vesting commencement date, while Dorman’s was granted at hire .
Equity Ownership & Alignment
| As of March 31, 2025 | Outstanding Shares Owned | Shares Exercisable Within 60 Days | Total Beneficially Owned | Ownership % |
|---|---|---|---|---|
| Stuart C. Dorman | — | — | — | <1% (*) |
- Options granted in Dec 2024 had not reached first vesting milestone by Mar 31, 2025; none were exercisable within 60 days of that date .
- Company provides limited perquisites; no tax gross-ups are generally provided, supporting alignment with shareholders .
Employment Terms
| Scenario | Cash Severance | Target Bonus | Healthcare Continuation | Equity Treatment |
|---|---|---|---|---|
| Termination without Cause or resignation for Good Reason (outside Change-in-Control period) | $375,000 | — | $27,939 | No acceleration |
| Termination without Cause or resignation for Good Reason (within Change-in-Control period) | $500,000 | $200,000 | $37,252 | Full acceleration of equity awards (double-trigger) |
- Definitions of “Cause,” “Change in Control,” and “Good Reason” are specified in executive employment agreements .
- Acceleration value for Dorman shown as “—” at 12/31/2024, reflecting options underwater at year-end (stock price $25.70 vs. $27.45 strike) .
Investment Implications
- Alignment and low near-term selling pressure: As of Mar 31, 2025, Dorman had no beneficially owned shares and no options exercisable within 60 days; 2024 options were unvested, reducing immediate selling pressure risk .
- Pay-for-performance structure: Annual bonus targets weighted 70% to clinical/preclinical milestones and 30% to corporate development (including launch readiness for darovasertib), with a small 2024 payout ($20k on a $200k target) consistent with hire timing and rigorous goals .
- Equity alignment and retention: Options vest over four years with a one-year cliff, promoting retention; double-trigger full acceleration in a change-in-control mitigates job-loss risk but could reduce retention post-close—important in M&A scenarios .
- Underwater options at YE 2024 (strike $27.45 vs $25.70 close) suggest future value realization requires execution on pipeline/launch targets; equity upside aligns Dorman’s incentives with TSR and commercialization success .
- Governance quality signals: No tax gross-ups, limited perquisites, and option pricing at grant-date close support shareholder-friendly practices; equity awards sized using peer benchmarks (50th/75th percentile) and company performance context .